Compounds > n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide
Page last updated: 2024-10-15

n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide

Cross-References

ID SourceID
PubMed CID135659046
CHEMBL ID597845
CHEBI ID94426
SCHEMBL ID8103931
SCHEMBL ID16445054
MeSH IDM0534136

Synonyms (39)

Synonym
salermide ,
CHEMBL597845 ,
bdbm50309827
1105698-15-4
n-{3-[(2-hydroxy-naphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide
S8460
BRD-A67788537-001-01-7
CCG-208708
SCHEMBL8103931
n-[3-[[(2-hydroxy-1-naphthalenyl)methylene]amino]phenyl]-?-methylbenzeneacetamide
AKOS024457988
HMS3648G04
SCHEMBL16445054
J-002449
HY-101073
CS-6203
EX-A1238
DTXSID70693943
n-[3-[(2-hydroxynaphthalen-1-yl)methylideneamino]phenyl]-2-phenylpropanamide
CHEBI:94426
n-(3-((2-hydroxynaphthalen-1-yl)methyleneamino)phenyl)-2-phenylpropanamide
salermide, >=98% (hplc)
n-(3-(((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)-2-phenylpropanamide
(e)-n-(3-(((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)-2-phenylpropanamide
AKOS032947358
BCP19469
Q27166286
n-[3-[(2-oxo-1-naphthalenylidene)methylamino]phenyl]-2-phenylpropanamide
sirt1/2 inhibitor viii, salermide - cas 1105698-15-4
n-[3-[[(2-hydroxy-1-naphthalenyl)methylene]amino]phenyl]-alpha-methylbenzeneacetamide
BS-14362
SR-01000946363-1
sr-01000946363
n-[3-[[(2-hydroxy-1-naphthalenyl)methylene]amino]phenyl]-a-methyl-benzeneacetamide
C71361
n-[3-[[(z)-(2-oxonaphthalen-1-ylidene)methyl]amino]phenyl]-2-phenylpropanamide
AC-35496
PD087406
PD065022
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)30.04290.50003.848110.0000AID1119559; AID1280430; AID1322347; AID460416; AID700823; AID708892; AID735756
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)IC50 (µMol)54.35000.00601.62509.0000AID1119558; AID1280429; AID1317158; AID1322346; AID460415; AID700824; AID708893; AID735757
NAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)IC50 (µMol)16.70000.85005.430010.0000AID1322348
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (156)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
aerobic respirationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of superoxide dismutase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of catalase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of ceramide biosynthetic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein-containing complexNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1176365Inhibition of human recombinant SIRT2 at 25 uM2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1119564Inhibition of SIRT1 in human MCF7 cells assessed as increase in acetylation of H3-K9 up to 50 uM after 24 hrs by Western blot analysis2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID708886Induction of apoptosis in human U937 cells after 45 hrs by flow cytometry2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1371048Antiparasitic activity against Schistosoma mansoni assessed cell viability at 20 uM after 4 days2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID708884Antiproliferative activity against human MOLT4 cells at 25 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID460417Protection against mutant PABPN1-induced toxicity in transgenic Caenorhabditis elegans coexpressing nuclear GFP and PABPN1-A13 assessed as inhibition of nuclear collapse2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1371078Antiparasitic activity against Schistosoma mansoni assessed as pairing at 20 uM after 5 days relative to control2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1530562Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition at 10 uM after 48 hrs by SYBR green1 staining based flow cytometry relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID708878Antiproliferative activity against human MOLT4 cells at 100 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1322352Selectivity ratio of IC50 for recombinant human His6-tagged SIRT3 to IC50 for recombinant human His6-tagged SIRT2
AID460426Effect on nuclear integrity in transgenic Caenorhabditis elegans coexpressing nuclear GFP and normal PABPN1-A102010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1280430Inhibition of His-tagged recombinant human SIRT2 after 60 mins by fluorescence assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
AID708882Antiproliferative activity against human RKO cells at 25 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1119572Cell cycle arrest in human MCF7 cells assessed as accumulation at G2-M phase at 50 uM after 24 hrs by flow cytometry (Rvb = 22.6 %)2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID708891Induction of apoptosis in human U937 cells at 5 uM after 45 hrs by flow cytometry2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID708881Antiproliferative activity against human MOLT4 cells at 50 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1280429Inhibition of His-tagged recombinant human SIRT1 after 60 mins by fluorescence assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
AID708880Antiproliferative activity against human RKO cells at 50 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1322348Inhibition of recombinant human His6-tagged SIRT3 using H2N-HK-[Nepsilon-acetyl-lysine]-LM-COOH as substrate incubated for 10 mins in presence of beta-NAD+ by HPLC based assay
AID708873Cytotoxicity against human 30PT cells after 72 hrs by celltiter-glo luminescent assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID708877Antiproliferative activity against human MOLT4 cells at 100 uM by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID708876Cytotoxicity against human CRO cells after 72 hrs by celltiter-glo luminescent assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1119565Inhibition of SIRT2 in human MCF7 cells assessed as increase in hyperacetylation of alpha-tubulin up to 50 uM after 24 hrs by Western blot analysis2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID700824Inhibition of SIRT12011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
SIRT1 modulation as a novel approach to the treatment of diseases of aging.
AID1119568Antiproliferative activity against human MCF7 cells at 30 uM after 24 to 72 hrs2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119569Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G1 phase at 50 uM after 24 hrs by flow cytometry (Rvb = 0.3 %)2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119558Inhibition of recombinant human N-tagged GST-SIRT1 fusion protein using fluorescent ZMAL as substrate after 4 hrs by homogeneous fluorescent deacetylase assay2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID460415Inhibition of human recombinant SIRT1 by Flour de Lys assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID708874Cytotoxicity against human 30P cells after 72 hrs by celltiter-glo luminescent assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1371058Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi at 5 uM by Alamar Blue assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1119567Inhibition of SIRT1 in human MCF7 cells assessed as increase in acetylation of p53 at lys 382 at 50 uM after 24 hrs by Western blot analysis2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID708883Antiproliferative activity against human MDA-MB-231 cells at 25 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1322351Selectivity ratio of IC50 for recombinant human His6-tagged SIRT3 to IC50 for recombinant human GST or His6-tagged SIRT1
AID1119570Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 50 uM after 24 hrs by flow cytometry (Rvb = 43.5 %)2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID708893Inhibition of human N-terminal GST-tagged SIRT1 expressed in Escherichia coli using Arg-His- Lys-Lys(Ac) as substrate after 1 hr by Fluor de Lys fluorescence based assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1322346Inhibition of recombinant human GST or His6-tagged SIRT1 using H2N-HK-[Nepsilon-acetyl-lysine]-LM-COOH as substrate incubated for 10 mins in presence of beta-NAD+ by HPLC based assay
AID1371059Inhibition of recombinant Trypanosoma cruzi Sir2rp32017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID735756Inhibition of human His6-tagged SIRT2 expressed in Escherichia coli BL21(DE3) assessed as inhibition of ZMAL conversion to ZML after 4 hrs by fluorescence assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
AID1119571Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 50 uM after 24 hrs by flow cytometry (Rvb = 30.8 %)2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID708888Cell cycle arrest in human U937 cells assessed as accumulation at G1 phase at 25 uM after 40 hrs by flow cytometry2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID708875Cytotoxicity against human CRC 1.1 cells after 72 hrs by celltiter-glo luminescent assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID708890Induction of apoptosis in human U937 cells at 50 uM after 45 hrs by flow cytometry2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID1317158Inhibition of recombinant human His-tagged SIRT1 assessed as inhibition of deacetylase activity measured after 60 mins by Fluor de Lys assay2016European journal of medicinal chemistry, Aug-25, Volume: 119How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
AID708879Antiproliferative activity against human MDA-MB-231 cells at 50 uM after 24 to 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID723620Inhibition of human Sirt5 desuccinylation activity using SKEYFS-succinylLys-QK as substrate at 100 uM after 60 mins by glutamate dehydrpgenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID700823Inhibition of SIRT22011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
SIRT1 modulation as a novel approach to the treatment of diseases of aging.
AID1119559Inhibition of recombinant human full length SIRT2 using fluorescent ZMAL as substrate after 4 hrs by homogeneous fluorescent deacetylase assay2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1322347Inhibition of recombinant human His6-tagged SIRT2 using H2N-HK-[Nepsilon-acetyl-lysine]-LM-COOH as substrate incubated for 12 mins in presence of beta-NAD+ by HPLC based assay
AID1322349Inhibition of recombinant human GST-tagged SIRT5 using CH3CONH-AR-[Nepsilon-succinyl-lysine]-ST-CONH2 as substrate incubated for 5 mins in presence of beta-NAD+ by HPLC based assay
AID735757Inhibition of human GST-tagged SIRT1 expressed in Escherichia coli BL21(DE3) assessed as inhibition of ZMAL conversion to ZML after 4 hrs by fluorescence assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
AID460416Inhibition of human recombinant SIRT2 by Flour de Lys assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1371049Antiparasitic activity against Schistosoma mansoni assessed as cumulative egg reduction at 20 uM2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1322350Inhibition of recombinant human His6-tagged SIRT6 using H2N-EALPK-[Nepsilon-myristoyl-lysine]-TGGPQ-CONH2 as substrate incubated for 12 mins in presence of beta-NAD+ by HPLC based assay
AID1530563Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 48 hrs by SYBR green1 staining based flow cytometry2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID708892Inhibition of human SIRT2 expressed in Escherichia coli using Gln-Pro-Lys-Lys(Ac) as substrate after 1 hr by Fluor de Lys fluorescence based assay2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
AID723626Inhibition of human Sirt5 deacetylation activity using FKRGVL-acetylLys-EYGVKV as substrate at 100 uM after 60 mins by glutamate dehydrogenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		4.6540pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.2110aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		3.2510branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
entinostat
[no description available]		2.2110benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
fenamic acid
fenamic acid: has chloride and potassium channel-blocking activity; RN given refers to parent cpd. fenamic acid : An aminobenzoic acid that is the N-phenyl derivative of anthranilic acid. It acts as a parent skeleton for the synthesis of several non-steroidal anti-inflammatory drugs.		3.2310aminobenzoic acid;
secondary amino compound		membrane transport modulator
suberoyl bis-hydroxamic acid
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor		3.2510hydroxamic acid
scriptaid
scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source		3.2510isoquinolines
fenofibrate
[no description available]		3.5920benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.2510dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.4920naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
suramin sodium
suramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.		4.520organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
dibenzylamine
10,11-dihydro-5H-dibenzo(b,f)azepine: core structure of clomipramine		2.0710
10,11-dihydrocarbamazepine
[no description available]		2.0710
toxoflavin
toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.		3.2310carbonyl compound;
pyrimidotriazine		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor
schizandrin a
schizandrin A: the major lignan, 2-9%, of Schisandra plant; has hepatoprotective, antioxidant, and antineoplastic activities		3.2310
hyperforin
hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.		3.2310
surfactin c
surfactin C : A cyclodepsipeptide that is N-[(3R)-3-hydroxy-13-methyltetradecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group.		3.2510cyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
platelet aggregation inhibitor;
surfactant
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.6820antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		4.1520resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
5-carboxy-8-hydroxyquinoline
5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source		2.2110quinolines
3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide
3-(1-azepanylsulfonyl)-N-(3-bromphenyl)benzamide: a sirtuin 2 inhibitor; structure in first source		2.4920
CAY10591
CAY10591: a SIRT1 NAD-dependent histone deacetylase activator		3.2310quinoxaline derivative
sirtinol
[no description available]		6.4580aldimine;
benzamides;
naphthols		anti-inflammatory agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Sir2 inhibitor
cambinol
cambinol: inhibitor of human silent information regulator 2 enzymes; structure in first source		5.3130
ex 527
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.		5.1950carbazoles;
monocarboxylic acid amide;
organochlorine compound
quercetin
[no description available]		4.08107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
pterostilbene
[no description available]		3.2310diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
ginsenoside rb2
[no description available]		3.231012beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		antiviral agent;
hypoglycemic agent;
plant metabolite
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
[no description available]		3.2510oligopeptide
belinostat
[no description available]		3.2510hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		3.2510cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
ginsenoside f1
ginsenoside F1: from ginseng. ginsenoside F1 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.		3.231012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
6alpha-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		apoptosis inhibitor;
plant metabolite
ginsenoside rc
[no description available]		3.231012beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		hypoglycemic agent;
plant metabolite
srt1720
[no description available]		2.0810
tenovin-6
tenovin-6 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide.		3.2310monocarboxylic acid amide;
tertiary amino compound;
thioureas		antineoplastic agent;
p53 activator;
Sir2 inhibitor
bix 01294
[no description available]		2.2110piperidines
unc 0638
UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source		2.2110quinazolines
pracinostat
pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.		3.2510benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
aristoforin
Aristoforin: derivative of hyperforin, is a potent anticancer agent; structure in first source		3.2310
ConditionIndicatedRelationship StrengthStudiesTrials
Oculopharyngeal Dystrophy
[description not available]		02.0510
Muscular Dystrophy, Oculopharyngeal
An autosomal dominant hereditary disease that presents in late in life and is characterized by DYSPHAGIA and progressive ptosis of the eyelids. Mutations in the gene for POLY(A)-BINDING PROTEIN II have been associated with oculopharyngeal muscular dystrophy.		02.0510
Diabetes Mellitus, Adult-Onset
[description not available]		03.8910
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		03.8910
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		03.8910